BIODESIX INC BDSX
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
3/9
Piotroski F — financial health
-19.59
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $88.5M | -$35.3M | — | -$23.5M | -$2.5M |
| 2024 | $71.3M | -$42.9M | — | -$51.9M | $20.9M |
| 2023 | $49.1M | -$52.1M | — | -$45.8M | $4.6M |
| 2022 | $38.2M | -$65.4M | — | -$48.3M | $20.6M |
| 2021 | $54.5M | -$43.2M | — | -$30.5M | $19.7M |
| 2020 | $45.6M | -$65.4M | — | -$23.3M | $41.2M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -19.59 (distress)
- Working capital / assets 0.172
- Retained earnings / assets -5.69
- EBIT / assets -0.319
- Equity / liabilities -0.027
Source: SEC EDGAR filings · CIK 0001439725 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.